Walleye Capital LLC Makes New $75,000 Investment in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Walleye Capital LLC bought a new position in Organogenesis Holdings Inc. (NASDAQ:ORGOGet Rating) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 15,355 shares of the company’s stock, valued at approximately $75,000.

Other institutional investors and hedge funds have also modified their holdings of the company. KBC Group NV purchased a new position in shares of Organogenesis during the 2nd quarter worth $27,000. Ameritas Investment Partners Inc. boosted its stake in shares of Organogenesis by 80.1% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,386 shares of the company’s stock worth $41,000 after acquiring an additional 2,396 shares during the last quarter. TrinityPoint Wealth LLC purchased a new position in shares of Organogenesis during the 2nd quarter worth $63,000. Lazard Asset Management LLC boosted its stake in shares of Organogenesis by 3,808.2% during the 1st quarter. Lazard Asset Management LLC now owns 9,106 shares of the company’s stock worth $69,000 after acquiring an additional 8,873 shares during the last quarter. Finally, Arizona State Retirement System purchased a new position in shares of Organogenesis during the 2nd quarter worth $77,000. Hedge funds and other institutional investors own 44.55% of the company’s stock.

Organogenesis Stock Down 0.4 %

ORGO opened at $2.59 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.31 and a current ratio of 2.58. Organogenesis Holdings Inc. has a fifty-two week low of $2.23 and a fifty-two week high of $10.66. The firm’s fifty day moving average is $3.20 and its 200 day moving average is $4.45. The stock has a market cap of $339.07 million, a price-to-earnings ratio of 5.63 and a beta of 1.73.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ORGO shares. Oppenheimer cut shares of Organogenesis from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 10th. BTIG Research cut shares of Organogenesis from a “buy” rating to a “neutral” rating in a research note on Thursday, November 10th.

Organogenesis Company Profile

(Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Read More

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.